Q-omics provides the consensus-scored PRB1 profile across patient tissues and cancer cell-line models. PRB1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PRB1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PRB1 RNA expression shows 5,093 significant pathway-activity associations, with the highest sampling consensus in LGG. Together, these results highlight KICH, HNSC, and LGG as cancer lineages where PRB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRB1 survival associations across molecular data types. PRB1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRB1 RNA expression–survival associations across cancer types. High PRB1 expression shows unfavorable associations in KICH, COAD, MESO, BRCA, PAAD and DLBC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PRB1 RNA expression.
This table summarizes PRB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRB1 shows lower tumor expression in HNSC and higher tumor expression in BRCA, COAD and KICH. The HNSC box plot shows higher PRB1 RNA expression in normal versus tumor tissue (log2 FC = −0.936, t-test p = .008).
This table shows molecular features associated with PRB1 in patient tissues and cancer cell lines. In patient samples, PRB1 shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set. In cancer cell lines, PRB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
